Table 2.

Functions of ARE-Containing Genes Synergistically Regulated by Oncogenic Ras and TGF-β

Gene SymbolGene NameRat Ensembl Gene IDFold Change
TGF-βRasV12RasV12 + TGF-β
Adhesion and motility
    Nrg1Neuregulin 1ENSRNOG00000010392−0.023.154.38
    PodxlPodocalyxin likeENSRNOG00000012495−1.34−1.65−2.90
    MarcksMyristoylated alanine-rich protein kinase C substrateENSRNOG000000005790.011.383.20
    Vnn1Vanin 1ENSRNOG00000016219−2.09−5.77−7.94
    GneGlucosamineENSRNOG000000143651.774.116.52
    Olr1Oxidized low-density lipoprotein (lectin-like) receptor 1ENSRNOG00000008375−1.84−4.26−21.26
    Col14a1Procollagen, type XIV, α1 (predicted)ENSRNOG00000026415−1.67−8.14−13.31
    Igsf4aImmunoglobulin superfamily, member 4AENSRNOG00000018778−1.33−2.11−4.23
    Lamc2Laminin, γ2ENSRNOG000000026671.787.499.63
    CxadrCoxsackie virus and adenovirus receptorENSRNOG00000001557−1.65−7.32−10.53
    Ctnnal1Catenin (cadherin-associated protein), α-like 1 (predicted)ENSRNOG00000010593−2.57−2.31−7.18
Angiogenesis
    VegfaVascular endothelial growth factorENSRNOG000000195981.455.907.52
    Fgf13Fibroblast growth factor 13ENSRNOG00000003523−1.29−7.46−13.92
Growth and proliferation
    Gas6Growth arrest–specific 6ENSRNOG00000018233−2.08−10.17−27.00
    NppbNatriuretic peptide precursor type BENSRNOG000000081412.739.1714.57
    Fhl1Four and a half LIM domains 1ENSRNOG000000008751.30−11.85−18.74
    Dusp1Dual specificity phosphatase 1ENSRNOG000000039771.85−1.03−3.36
    Mycnv-myc myelocytomatosis viral-related oncogene, neuroblastoma derived (avian)ENSRNOG00000006308−1.58−18.99−67.66
Transcription
    Klf4Kruppel-like factor 4 (6)ENSRNOG00000016299−1.291.04−2.54
    Id2Inhibitor of DNA binding 2ENSRNOG00000007237−3.40−2.15−6.66
    Tcf7Transcription factor 7, T-cell specific (predicted)ENSRNOG000000058721.85−1.1020.51
    Stat1Signal transducer and activator of transcription 2ENSRNOG00000014079−1.80−1.28−3.16
    Nrg1Neuregulin 1ENSRNOG00000010392−0.023.154.38
Extracellular matrix related
    Adamts1A disintegrin-like and metallopeptidase with thrombospondin type 1 motif, 1ENSRNOG00000001607−2.32−12.63−19.39
    Col14a1Procollagen, type XIV, α1 (predicted)ENSRNOG00000026415−1.67−8.14−13.31
    Mmp13Matrix metallopeptidase 13ENSRNOG000000084782.183.2323.10
    Mmp10Matrix metallopeptidase 10ENSRNOG000000328321.242.714.10
Cytoskeleton
    MarcksMyristoylated alanine-rich protein kinase C substrateENSRNOG000000005790.011.383.20
    Map1bMicrotubule-associated protein 1bENSRNOG000000174284.015.379.94
    Ctnnal1Catenin (cadherin-associated protein), α-like 1 (predicted)ENSRNOG00000010593−2.57−2.31−7.18
    CavCaveolinENSRNOG00000006694−1.68−2.13−5.01
RNA-binding proteins
    Zfp36l1Zinc finger protein 36, C3H type-like 1ENSRNOG00000030024−2.35−2.13−6.25
    CUGBP2CUG triplet repeat, RNA-binding protein 2ENSRNOG00000023661−2.01−2.58−5.64
    A2bp1Ataxin 2–binding proteinENSRNOG00000002827−1.423.094.71
Growth factors and cytokines
    Nrg1Neuregulin 1ENSRNOG00000010392−0.023.154.38
    PdgfaPlatelet-derived growth factor, αENSRNOG000000013121.302.246.74
    Il24Interleukin-24ENSRNOG000000044701.302.9523.63
    Il1aInterleukin-1αENSRNOG000000045751.081.4616.17
    Ccl2Chemokine (C-C motif) ligand 2ENSRNOG000000071595.4717.2837.90
    BtcBetacellulinENSRNOG00000002728−1.58−7.33−11.47
Wnt signaling
    Wnt5aWingless-type MMTV integration site 5AENSRNOG000000156181.092.987.41
    Wnt2Wingless-related MMTV integration site 2ENSRNOG000000078432.491.167.79
    Fzd1Frizzled homologue 1 (Drosophila)ENSRNOG000000162421.201.242.70
    Axin2Axin2ENSRNOG000000036121.422.264.26
TGF-β signaling
    Bmp4Bone morphogenetic protein 4ENSRNOG00000009694−1.90−10.34−18.82
    Bmp2Bone morphogenetic protein 2ENSRNOG000000212761.8120.1025.40
    Serpine1Serine (or cysteine) peptidase inhibitor, clade E, member 1 (PAI-1)ENSRNOG0000000141433.574.6057.69
  • NOTE: All genes listed in the table are significantly and synergistically regulated by a combination of Ras induction and TGF-β treatment and contain an ARE motif in the 3′-UTR. Fold change represents expression in Ras-expressing and/or TGF-β–treated samples compared with untreated. Presence of an ARE was determined by analysis using the ARE database ARED3.0 (35).